-
EP2370092
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2370092
| EP2370092 - MODULATION OF OLFML-3 MEDIATED ANGIOGENESIS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.05.2015 Database last updated on 22.05.2024 | Most recent event Tooltip | 01.05.2015 | Application deemed to be withdrawn | published on 03.06.2015 [2015/23] | Applicant(s) | For all designated states Research Development Foundation 402 North Division Street Carson City, NV 89703 / US | [2011/40] | Inventor(s) | 01 /
IMHOF, Beat, A. University of Geneva Centre Medical Universitaire rue Michel Servet 1 CH-1211 Geneva 4 / CH | 02 /
MILJKOVIC-LICINA, Marijana University of Geneva Centre Medical Universitaire rue Michel Servet 1 CH-1211 Geneva 4 / CH | 03 /
HAMMEL, Philippe University of Geneva Centre Medical Universitaire rue Michel Servet 1 CH-1211 Geneva 4 / CH | [2011/40] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [N/P] |
| Former [2011/40] | Vossius & Partner Siebertstrasse 4 81675 München / DE | Application number, filing date | 09764421.5 | 30.11.2009 | WO2009US66054 | Priority number, date | US20080119551P | 03.12.2008 Original published format: US 119551 P | [2011/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010065437 | Date: | 10.06.2010 | Language: | EN | [2010/23] | Type: | A1 Application with search report | No.: | EP2370092 | Date: | 05.10.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.06.2010 takes the place of the publication of the European patent application. | [2011/40] | Search report(s) | International search report - published on: | EP | 10.06.2010 | Classification | IPC: | A61K38/17, A61K39/00, C12N15/11 | [2011/40] | CPC: |
C07K16/18 (EP,US);
A61P1/00 (EP);
A61P1/18 (EP);
A61P17/02 (EP);
A61P19/02 (EP);
A61P27/02 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P41/00 (EP);
A61P9/00 (EP);
C12N15/113 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Title | German: | VERÄNDERUNG DER OLFML-3 VERMITTELTEN ANGIOGENESE | [2014/33] | English: | MODULATION OF OLFML-3 MEDIATED ANGIOGENESIS | [2011/40] | French: | MODULATION DE L'ANGIOGENESE TRANSMIS PAR OLFML-3 | [2014/33] |
| Former [2011/40] | MODULIERUNG VON OLFML-3-VERMITTELTER ANGIOGENESE | ||
| Former [2011/40] | MODULATION DE L'ANGIOGENÈSE À MÉDIATION PAR OLFML-3 | Entry into regional phase | 30.06.2011 | National basic fee paid | 30.06.2011 | Designation fee(s) paid | 30.06.2011 | Examination fee paid | Examination procedure | 30.06.2011 | Amendment by applicant (claims and/or description) | 30.06.2011 | Examination requested [2011/40] | 19.11.2013 | Despatch of a communication from the examining division (Time limit: M04) | 07.03.2014 | Reply to a communication from the examining division | 24.07.2014 | Communication of intention to grant the patent | 04.12.2014 | Application deemed to be withdrawn, date of legal effect [2015/23] | 14.01.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2015/23] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 19.11.2013 | Fees paid | Renewal fee | 23.11.2011 | Renewal fee patent year 03 | 27.11.2012 | Renewal fee patent year 04 | 18.11.2013 | Renewal fee patent year 05 | 10.11.2014 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2004112566 (QUARK BIOTECH INC [US], et al) [X] 1-3,8-9,15,20-25,27,32-33 * page 12; example 15; claims 30-37 * [I] 4-7,10-14,16-19,26,28-31,34-35; | [X]WO2004112565 (QUARK BIOTECH INC [US], et al) [X] 1-3,8-9,15,20-25,27 * example 15; claims 27-30,32,33 *; | [X]WO2008036741 (ASURAGEN INC [US], et al) [X] 1-2,15,27 * claims 1-4 *; | [XD] - SAKURAGI ET AL, "Functional analysis of chick ONT1 reveals distinguishable activities among olfactomedin-related signaling factors", MECHANISMS OF DEVELOPMENT, ELSEVIER SCIENCE IRELAND LTD, IE, (20060201), vol. 123, no. 2, ISSN 0925-4773, pages 114 - 123, XP005290458 [XD] 1-2,15,27 * the whole document * DOI: http://dx.doi.org/10.1016/j.mod.2005.11.005 | [XD] - ZENG L-C ET AL, "hOLF44, a secreted glycoprotein with distinct expression pattern, belongs to an uncharacterized olfactomedin-like subfamily newly identified by phylogenetic analysis", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20040730), vol. 571, no. 1-3, ISSN 0014-5793, pages 74 - 80, XP004523315 [XD] 8-9,15,27 * the whole document * DOI: http://dx.doi.org/10.1016/j.febslet.2004.06.059 | [AD] - INOMATA HIDEHIKO ET AL, "Robust stability of the embryonic axial pattern requires a secreted scaffold for chordin degradation.", CELL 5 SEP 2008, (20080905), vol. 134, no. 5, ISSN 1097-4172, pages 854 - 865, XP002569814 [AD] 1-35 * the whole document * DOI: http://dx.doi.org/10.1016/J.CELL.2008.07.008 | [AD] - IKEYA MAKOTO ET AL, "Gene disruption/knock-in analysis of mONT3: vector construction by employing both in vivo and in vitro recombinations.", THE INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY 2005, (2005), vol. 49, no. 7, ISSN 0214-6282, pages 807 - 823, XP002569815 [AD] 1-35 * the whole document * DOI: http://dx.doi.org/10.1387/ijdb.051975mi | [AD] - AHMED FARID ET AL, "Gene expression profile of the rat eye iridocorneal angle: NEIBank expressed sequence tag analysis.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE SEP 2004, (200409), vol. 45, no. 9, ISSN 0146-0404, pages 3081 - 3090, XP002569816 [AD] 1-35 DOI: http://dx.doi.org/10.1167/iovs.04-0302 | [ADP] - TOMAREV STANISLAV I ET AL, "Olfactomedin Domain-Containing Proteins: Possible Mechanisms of Action and Functions in Normal Development and Pathology", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, (20090626), vol. 40, no. 2, ISSN 0893-7648, pages 122 - 138, XP009127647 [ADP] 1-35 * page 129, column r; table 1 * DOI: http://dx.doi.org/10.1007/s12035-009-8076-x | Examination | - M. Miljkovic-Licina ET AL, "Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage", Molecular Cancer Therapeutics, (20120920), vol. 11, no. 12, doi:10.1158/1535-7163.MCT-12-0245, ISSN 1535-7163, pages 2588 - 2599, XP055088067 DOI: http://dx.doi.org/10.1158/1535-7163.MCT-12-0245 | by applicant | US3817837 | US3850752 | US3939350 | US3996345 | US4196265 | US4275149 | US4277437 | US4366241 | US4469797 | US4472509 | US4606855 | US4703003 | US4742159 | US4767720 | US4816567 | US4867973 | US4870287 | US4938948 | US4946778 | US5021236 | US5091513 | US5164296 | US5196066 | US5223409 | US5403484 | US5420253 | US5565332 | US5571698 | US5627052 | US5656434 | US5770376 | US5789208 | US5821337 | US5844091 | US5858657 | US5861155 | US5871907 | US5969108 | US6054297 | US6165464 | US6365157 | US6406867 | US2002168707 | US2002172677 | US6506559 | US2003051263 | US2003055020 | US6573099 | US2003159161 | US6673611 | US2004019001 | US6709659 | US6709873 | US2004064842 | US6753407 | US2004126828 | US6814965 | US2004265839 | US6849259 | US6861572 | US6875434 | US6891024 | US2005214860 | US7122181 |